Home › Compare › DELCF vs ABBV
DELCF yields 1000000.00% · ABBV yields 3.06%● Live data
📍 DELCF pulled ahead of the other in Year 1
Combined, DELCF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DELCF + ABBV for your $10,000?
Delic Holdings Corp. provides various medicines and treatments in the United States and Canada. It operates The Delic, a creative platform that creates and hosts public discourse about psychedelic culture; Meet Delic, which organizes event to promote topics, such as safety and harm reduction, Hollywood, mental health and psychedelics, the power of integration, human performance, medicine, and other topics; Reality Sandwich, a public online education platform with approximately 10,000 pieces of content, including psychedelic guides, news, and culture; and Delic Radio, a podcast that discusses topics related to the psychedelic space with experts comprising discussions relating to news, science, culture, medicine, current affairs, and policy. The company also focuses on developing intellectual property through research and development for cannabis and psychedelics. In addition, it owns and operates two ketamine infusion treatment clinics; and thirteen ketamine infusion treatment clinics. The company is headquartered in Vancouver, Canada.
Full DELCF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.